HeartFlow announced positive seven-year data supporting the use of its AI-enabled fractional flow reserve computed tomography (FFRCT) and Plaque Analysis.
This study assessed long-term risk of coronary artery disease (CAD) in clinically stable, symptomatic patients. Outcomes showed that the HeartFlow platform provides clinicians with the insights needed to anticipate and mitigate adverse events. That includes myocardial infarctions in symptomatic patients with stable chest pain.
The company had its data presented at Transcatheter Cardiovascular Therapeutics (TCT) 2024 in Washington, D.C.
ADVANCE-DK, a subset of the larger ADVANCE registry, evaluated the use of a coronary computed tomography angiography (CCTA) and FFRCT diagnostic pathway in real-world settings to determine the impact on decision-making, downstream invasive coronary angiography (ICA), revascularization, and major adverse cardiovascular events (MACE). It assessed three patient sets. First, it looked at those with normal FFRCT, then those with subsequent complete revascularization (CR). Finally, it evaluated those with subsequent incomplete revascularization (IR).
Data demonstrated the completeness of revascularization predicts clinical outcomes and can be assessed non-invasively using coronary CCTA and FFRCT. Patients with IR as assessed by FFRCT had a higher long-term risk of adverse events than those whose assessment showed CR or patients who had a normal FFRCT. Combined plaque quantification and characterization and lesion-specific physiology from FFRCT also proved a superior predictor of adverse cardiovascular events.
Dr. Kristian Tækker Madsen of Denmark said: “FFRCT remains valuable for patients across all categories, and the combination of FFRCT and quantitative plaque data, especially after four years of follow up, can offer providers invaluable insight into a patient’s long-term risks informing more personalized and effective treatment plans.”